A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]

HIK Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £46,340
Insider Selling (Last 12 Months): £546,660.24

Hikma Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Hikma Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Hikma Pharmaceuticals Share Price & Price History

Current Price: GBX 1,733.50
Price Change: Price Increase of +21.5 (1.26%)
As of 02/3/2023 01:00 AM ET

This chart shows the closing price history over time for HIK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]

Hikma Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2023Deneen VojtaInsiderBuy1,000GBX 1,703£17,030
3/14/2022Sigurdur OlafssonInsiderSell27,498GBX 1,988£546,660.24
3/3/2022Douglas HurtInsiderBuy1,500GBX 1,954£29,310
3/17/2021Mary (Nina) HendersonInsiderBuy1,600GBX 2,203£35,248
3/12/2021Sigurdur OlafssonInsiderSell31,794GBX 2,206£701,375.64
3/2/2021Douglas HurtInsiderBuy1,500GBX 2,265£33,975
5/13/2020Mazen DarwazahInsiderSell1,350,000GBX 2,450£33,075,000
See Full Table
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Click here for the full story

SEC Filings (Institutional Ownership Changes) for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals logo
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Read More on Hikma Pharmaceuticals

Today's Range

Now: GBX 1,733.50
Low: 1,694
High: 1,749

50 Day Range

MA: GBX 1,604.41
Low: 1,481
High: 1,734

52 Week Range

Now: GBX 1,733.50
Low: 1,174.50
High: 2,137

Volume

307,469 shs

Average Volume

444,485 shs

Market Capitalization

£3.82 billion

P/E Ratio

1,420.90

Dividend Yield

2.54%

Beta

N/A

Who are the company insiders with the largest holdings of Hikma Pharmaceuticals?

Hikma Pharmaceuticals' top insider shareholders include:
  1. Deneen Vojta (Insider)
  2. Douglas Hurt (Insider)
  3. Mary (Nina) Henderson (Insider)
  4. Sigurdur Olafsson (Insider)
Learn More about top insider investors at Hikma Pharmaceuticals.
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]